Shares of AstraZeneca plc (LON:AZN) have been given a consensus rating of “Hold” by the nineteen brokerages that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is GBX 6,693.75 ($87.47).
Several research analysts have recently issued reports on AZN shares. Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research note on Wednesday. Deutsche Bank reiterated a “buy” rating and issued a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a report on Friday, July 26th. Morgan Stanley lifted their price objective on shares of AstraZeneca from GBX 6,400 ($83.63) to GBX 6,500 ($84.93) and gave the company an “equal weight” rating in a report on Tuesday, May 7th. Kepler Capital Markets set a GBX 6,470 ($84.54) price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Monday, May 13th. Finally, Barclays set a GBX 7,600 ($99.31) price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Friday, August 9th.
AZN stock traded down GBX 39 ($0.51) during trading hours on Friday, hitting GBX 7,230 ($94.47). The company’s stock had a trading volume of 1,454,027 shares, compared to its average volume of 2,310,000. The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The stock has a market cap of $94.85 billion and a P/E ratio of 42.23. AstraZeneca has a 12 month low of GBX 5,312 ($69.41) and a 12 month high of GBX 7,349.30 ($96.03). The stock has a 50 day moving average of GBX 6,738.50.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Buy Rating
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.